| abstract |
Wherein X and Y are each N or C, at least one of X and Y is N, and Z is a single bond or an optionally substituted connecting (connecting) group. R1 is hydrogen or a substituent group; R2 is an amino or substituent group; N * is amino when R1 is hydrogen, and = NH when R1 is a substituent group; or N * is NRaRb, wherein Ra and Rb are independently H or an alkyl group; or N * is optionally an optionally substituted piperazinyl ring; And A is an optionally substituted heterocyclyl or carbocyclyl ring system that is linked to the triazo / diazo ring via R < 2 > to form a fused multlcyclic ring is selected from the group consisting of a sodium channel blocker and an antifolate The present invention relates to the use of a compound of formula I in the manufacture of a medicament for the treatment of diseases of the mammalian body which are susceptible to a disease or disorder selected from the group consisting of epilepsy, multiple infarction, glaucoma and uveitis, cerebral trauma and cerebral ischemia, seizures, head injuries, spinal cord injuries, Inflammatory pain, neuropathic pain, migraine, bipolar disorder, emotion, anxiety and cognitive disorders, schizophrenia and trigeminal neural autonomic neural headache; Cancer treatment of mammals; And is useful for treating malaria. |